Tag Archives: BIO

PTAB, IPRs and Uncertainty in the Patent System

shutterstock_26191726

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the last several years (see our archive for some of our past articles on the subject). As uncertainty grows in the biopharma community about IPR procedures and the future of innovation, BIO will make IPRs a major topic of discussion at our upcoming IP and Diagnostics Symposium (BIO IPDX) as well as BIO’s IP Counsels Committee Meeting in November. An administrative Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Releases Points to Consider on Truthful and Non-Misleading Product Communication

medical_research

Today, BIO releases Points to Consider on Truthful and Non-Misleading Product Communication. This document advances the dialogue on this issue toward achieving the shared aim of getting the right medicine to the right patient at the right time. The current “Information Age” holds significant promise to improve the ability of stakeholders to make well-informed healthcare decisions.  Never before has information about healthcare interventions, including innovative medicines, been so readily available from so many different sources and through Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Orphan Drug Tax Credit is Crucial to Rare Disease R&D

medical_research

The term “rare disease” may be misleading: to be “rare” a disease must effect fewer than 200,000 people in the U.S., but there are over 7,000 rare diseases that have been identified. Taken together, that means that nearly 30 million Americans suffer from a rare disease or condition.  While innovative therapies have been developed for a variety of these diseases—including Sickle Cell Anemia, Gaucher Disease, and Huntington Disease—too many patients still lack treatment options. Developing Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

IP Sessions at the 2015 BIO International Convention

BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues in the biotech IP sector.  The world’s largest biotechnology gathering, the convention offers attendees the chance to come together to hear, discuss, and learn about current issues affecting the biotech community. Here’s a look at the Intellectual Property Track at this year’s convention: Sessions* Intellectual Property Opening Plenary Antibody Therapeutics: May I Have Them All? The Impact of USPTO Inter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO Chair Testifies Before Senate

BIO’s Chair and CEO of GlycoMimetics, Rachel King

BIO’s Chair and CEO of GlycoMimetics, Rachel King, testified before the Senate Committee on Small Business and Entrepreneurship today where she reinforced the need for patent protection incentives to encourage small business innovation. Ms. King also encouraged Congress to address weaknesses in the United States Patent and Trademark Office’s Inter Partes Review (IRP) system that allows abuses perpetrated against legitimate patent holders. Read her full testimony. You can read more about BIO’s position on patent Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,